Nanotechnology approaches for global infectious diseases
Infectious diseases are a major driver of morbidity and mortality globally. Treatment of
malaria, tuberculosis and human immunodeficiency virus infection are particularly …
malaria, tuberculosis and human immunodeficiency virus infection are particularly …
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
V Agrahari, SM Anderson, MM Peet… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …
A year-long extended release nanoformulated cabotegravir prodrug
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …
Creation of a long-acting nanoformulated dolutegravir
Potent antiretroviral activities and a barrier to viral resistance characterize the human
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …
An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression
Treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy. However,
suboptimal adherence to the existing daily therapy has led to the need for ultralong-acting …
suboptimal adherence to the existing daily therapy has led to the need for ultralong-acting …
Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages
The use of antiretroviral therapy (ART) has remarkably decreased the morbidity associated
with HIV-1 infection, however, the prevalence of HIV-1-associated neurocognitive disorders …
with HIV-1 infection, however, the prevalence of HIV-1-associated neurocognitive disorders …
Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs
In spite of introduction of combination antiretroviral therapy (cART) against human
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …
Long-acting injectables: current perspectives and future promise
K Chaudhary, MM Patel… - Critical Reviews™ in …, 2019 - dl.begellhouse.com
The parenteral route of administration is preferred over the oral route for treatment of many
chronic and life-threatening diseases due to better patient compliance. Long-acting …
chronic and life-threatening diseases due to better patient compliance. Long-acting …
The promise of long-acting antiretroviral therapies: from need to manufacture
Antiretroviral therapy has transformed human immunodeficiency virus infections from certain
death to a manageable chronic disease. Achieving strict adherence to drug regimens that …
death to a manageable chronic disease. Achieving strict adherence to drug regimens that …